Hsp90-IN-46 是一种 Hsp90 抑制剂,对肿瘤细胞株具有广谱抗增殖活性,可通过减少集落形成和下调增殖标志物 Ki-67 抑制乳腺癌细胞增殖,并可抑制 Hsp90 及其 ATP 酶活性、下调下游底物癌蛋白 HER2 与 CDK4、适度诱导热休克反应,在三阴性乳腺癌肿瘤异种移植小鼠模型中具有显著抗肿瘤活性,可用于三阴性乳腺癌、白血病、非小细胞肺癌、结肠癌、卵巢癌、肾癌、前列腺癌等多种癌症的研究。
Hsp90-IN-46
产品编号: MS-D66220 分子式: C21H18BrN5O3 分子量: 468.30
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

Hsp90-IN-46 是一种 Hsp90 抑制剂,对肿瘤细胞株具有广谱抗增殖活性,可通过减少集落形成和下调增殖标志物 Ki-67 抑制乳腺癌细胞增殖,并可抑制 Hsp90 及其 ATP 酶活性、下调下游底物癌蛋白 HER2 与 CDK4、适度诱导热休克反应,在三阴性乳腺癌肿瘤异种移植小鼠模型中具有显著抗肿瘤活性,可用于三阴性乳腺癌、白血病、非小细胞肺癌、结肠癌、卵巢癌、肾癌、前列腺癌等多种癌症的研究。

生物实验数据

生物活性 Hsp90-IN-46 is an Hsp90 inhibitor that exhibits broad-spectrum antiproliferative activity against tumor cell lines, inhibits breast cancer cell proliferation by reducing colony formation and downregulating the proliferation marker Ki-67, suppresses Hsp90 and its ATPase activity, downregulates the downstream substrate oncoproteins HER2 and CDK4, and moderately induces the heat shock response, shows significant antitumor activity in a triple-negative breast cancer tumor xenograft mouse model, and can be used for research on various cancers including triple-negative breast cancer, leukemia, non-small cell lung cancer, colon cancer, ovarian cancer, renal cancer, and prostate cancer.
IC50 & Target

HSP90

 

体外研究
(In Vitro)

Hsp90-IN-46 (Compound 13b) (0.01-100 μM; 48 h) 在 48 种人类肿瘤细胞系中表现出强效、广谱的抗癌活性,其 GI50 值范围为 2.17 至 9.60 μM,可在 26 种细胞系中实现总生长抑制,且在 5 种浓度下作用 48 h 的测试中,对大多数细胞系的致死性极低。
Hsp90-IN-46 (48 h) 对 MCF-7 和 MDA-MB-231 乳腺癌细胞系具有高活性和选择性抑制作用,其 IC50 值分别为 1.33 μM 和 1.95 μM。
Hsp90-IN-46 (1-5 μM, 9 days) 抑制 MDA-MB-231 乳腺癌细胞增殖,降低 MCF-7 和 MDA-MB-231 乳腺癌细胞中增殖标志物 Ki67 的表达,下调 Hsp90 底物癌蛋白 HER2 和 CDK4 的表达。
Hsp90-IN-46 可在基于体外 AlphaLISA 的分析实验中直接抑制 Hsp90 的活性,其 IC50 为 12.397 μM,可在偶联分光光度法测定中强效抑制 Hsp90 ATP 酶活性,其 IC50 为 0.986 μM。
Hsp90-IN-46 (10 μM) 可在 HEK-293 细胞中诱导中度热休克反应,在 10 μM 浓度下使 HspA1A mRNA 表达水平升高 8.7 倍。

Cell Cytotoxicity Assay

Cell Line: 48 human tumor cell lines from multiple subpanels (NSCLC, colon, CNS, melanoma, ovarian, renal, prostate, leukemia, breast)
Concentration: 10 μM
Incubation Time: 48 h
Result: Exhibited a mean growth inhibition (GI%) of 78.84% across 48 cell lines.
Showed strong cytotoxicity (GI% 57.74-68.93%) against NSCLC (NCI-H226), colon (HCC-2998, HT29, SW-620), CNS (SF-539), melanoma (M14), ovarian (OVCAR-3, OVCAR-8), renal (A498, RXF 393), and prostate (DU-145) cancer cell lines.
Demonstrated potent cytotoxicity (GI% 70.24-97.44%) against all leukemia cell lines and most NSCLC, melanoma, colon, CNS, ovarian, renal, and breast cancer cell lines.
Induced 56.97% and 4.33% lethality against melanoma SK-MEL-5 and SK-MEL-2 cell lines, respectively.

Cell Cytotoxicity Assay

Cell Line: 60 human tumor cell lines
Concentration: 0.01-100 μM
Incubation Time: 48 h
Result: Demonstrated potent cytotoxicity with GI50 values of 2.17-9.60 μM against 48 cell lines.
Showed lower activity with GI50 values of 10.20-22.70 μM against 12 cell lines.
Induced total growth inhibition (TGI) with values of 6.23-91.00 μM against 26 cell lines (including breast MDA-MB-468, melanoma SK-MEL-5, UACC-62, SK-MEL-2, and ovarian OVCAR-3).
Exhibited minimal toxicity with LC50 >92.5 μM against 57 cell lines, except LC50 values of 27.40-61.30 μM against colon COLO 205 and melanoma SK-MEL-5, UACC-62 cell lines.
Achieved a full-panel GI50 mean graph-midpoint (MG-MID) value of 5.89 μM, with breast cancer MDA-MB-468 as the most sensitive cell line (GI50 = 2.17 μM) and ovarian cancer OVCAR-5 as the least sensitive (GI50 = 22.7 μM).

Cell Cytotoxicity Assay

Cell Line: MCF-7, MDA-MB-231, Caco-2, A549 cancer cell lines; normal human skin fibroblast (HSF) cells
Concentration: Serial concentrations
Incubation Time: 48 h
Result: Displayed IC50 values of 1.33 μM (MCF-7), 1.95 μM (MDA-MB-231), 4.62 μM (Caco-2), 11.89 μM (A549), and 46.96 μM (HSF).
Achieved selectivity index values of 35.31 (MCF-7), 24.08 (MDA-MB-231), 10.16 (Caco-2), and 3.95 (A549).

Cell Proliferation Assay

Cell Line: MDA-MB-231 breast cancer cells
Concentration: 5 μM
Incubation Time: 9 days
Result: Significantly reduced colony formation from 173 colonies per well (control) to 91 colonies per well.
体内研究
(In Vivo)

Hsp90-IN-46 (13b) (50 mg/kg; i.p.; daily; 6 days) 在三阴性乳腺癌肿瘤异种移植小鼠模型中具有显著的抗肿瘤活性。

Animal Model: BALB/c mice (immunocompromised)
Dosage: 50 mg/kg
Administration: i.p.; daily; 6 consecutive days
Result: Reduced MDA-MB-231 xenograft tumor volume and tumor weight by approximately 33%.
Reduced EGFR expression in tumor sections to 0.17-0.92% reaction area.
Maintained stable body weight in treated mice.

化学信息

分子量 468.30
分子式 C21H18BrN5O3

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础